CDH
NVIV

Charles D. Hyman’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Charles D. Hyman’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$16K – 184
2018
Q1 		$16K Hold
2
– – ﹤0.01% 177
2017
Q4 		$23K Hold
2
– – ﹤0.01% 167
2017
Q3 		$43K Hold
2
– – 0.01% 157
2017
Q2 		$81K Hold
2
– – 0.01% 153
2017
Q1 		$121K Hold
2
– – 0.02% 143
2016
Q4 		$126K Hold
2
– – 0.02% 136
2016
Q3 		$204K Hold
2
– – 0.03% 132
2016
Q2 		$186K Hold
2
– – 0.03% 136
2016
Q1 		$224K Buy
+2
New +$215K 0.04% 132

Other funds holding NVIV

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles D. Hyman's NVIV Position: Q2 2018 in Review

Charles D. Hyman sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2018, closing a stake of 2 shares — an estimated $16K sold.

Charles D. Hyman first reported a position in NVIV in Q1 2016 and held it in 9 quarters. The position peaked at $224K in Q1 2016. 17 funds tracked by Wall St. Rank hold NVIV as of Q2 2018.

  • Charles D. Hyman reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2018 after selling out during the quarter.
  • Charles D. Hyman sold 2 InVivo Therapeutics Holdings Corp shares in Q2 2018, an estimated $16K.
  • Charles D. Hyman first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 9 quarters.
  • Charles D. Hyman's InVivo Therapeutics Holdings Corp position peaked at $224K in Q1 2016.
  • 17 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2018.

Based on Charles D. Hyman's 13F filing for Q2 2018, filed 6 Aug 2018.